(Total Views: 736)
Posted On: 07/03/2025 4:35:10 AM
Post# of 154991
Quote:
The question for me is does that last sentence refer to the first phrase in the preceding sentence, or the second, or both? Frankly I end up thinking just the first, that is adding the monitoring of PD-L1 for upregulation.
Quote:
Ken Chowder. Very good question Ken! As you pointed out, CRC is known to be a cold tumor, not much PD-L1 expression. We hope to see a similar impact on PD-L1 upregulation prospectively with Leronlimab, allowing patients potentially to benefit from ICIs. That option has been added in the CRC study. Best!
PD-L1 testing in the trial would not be an option it would be done on all patients. The option must be the use of ICIs and there is only one CRC study underway where that option can be exercised.
(16)
(0)
